29
Participants
Start Date
January 31, 2017
Primary Completion Date
July 29, 2022
Study Completion Date
December 31, 2024
Marqibo
The focus of the study design and statistical analysis is to determine whether Marqibo® can be substituted for standard vincristine and successfully administered to patients with relapsed ALL in three different treatment cohorts: (A) treatment with the UK ALL R3 regimen; (B) treatment with UK ALL R3 regimen without mitoxantrone, and (C) treatment with ALL maintenance therapy. Secondary objectives include estimating rates of serious toxicities and therapy delays in each of these cohorts.
Sydney Children's Hospital, Randwick
The Children's Hospital at Westmead, Westmead
Royal Children's Hospital, Melbourne, Parkville
Lady Cilento Children's Hospital, South Brisbane
Children's Hospital New York-Presbyterian, New York
Children's Hospital of Philadelphia, Philadelphia
Children's National Medical Center, Washington D.C.
National Cancer Institute, Pediatric Oncology Branch, Bethesda
Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore
Levine Children's Hospital, Charlotte
Children's Healthcare of Atlanta at Egleston, Atlanta
University of Miami, Miami
All Children's Hospital, St. Petersburg
Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville
Nationwide Children's Hospital, Columbus
Rainbow Babies & Children's Hospital, Cleveland
Cincinnati Children's Hospital, Cincinnati
CS Mott Children's Hospital, Ann Arbor, Ann Arbor
Medical College of Wisconsin, Milwaukee
Children's Hospitals and Clinics of Minnesota, Minneapolis
Lurie Children's Hospital of Chicago, Chicago
University of Texas Southwestern Medical Center, Dallas
Cook Children's Medical Center, Fort Worth
Texas Children's Cancer Center, Baylor, Houston
The Children's Hospital, University of Colorado, Aurora
Primary Children's Hospital, Salt Lake City
Childrens Hospital Los Angeles, Los Angeles
Children's Hospital Orange County, Orange
UCSF School of Medicine, San Francisco
Oregon Health & Science University, Portland
Seattle Children's Hospital, Seattle
Dana-Farber Cancer Institute, Boston
British Columbia Children's Hospital, Vancouver
Hospital for Sick Children, Toronto
Sainte-Justine University Hospital Center, Montréal, Québec
Spectrum Pharmaceuticals, Inc
INDUSTRY
Therapeutic Advances in Childhood Leukemia Consortium
OTHER